Adiso Therapeutics
- Company typePrivate
- Founded2022
- HeadquartersConcord, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Adiso Therapeutics firmographics
Firmographics- Name
- Adiso Therapeutics
- Legal name
- Adiso Therapeutics
- Website
- https://adisotx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Adiso Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Concord
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Adiso Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Adiso Therapeutics product offering
Product offeringCore offering
Adiso Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of multi-modal therapeutic agents with novel mechanisms of action to treat inflammatory diseases. Its core assets are ADS032, a first-in-class dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for respiratory and dermal inflammation, and ADS024, an orally dosed single-strain live biotherapeutic product (SS-LBP) that acts via selective G-protein coupled receptor agonism and has demonstrated efficacy across multiple neurodegenerative disease models.
Product overview
Adiso Therapeutics is a biopharmaceutical company developing an innovative pipeline of multi-modal agents with novel mechanisms of action for the treatment of inflammatory diseases. The company's portfolio consists of two core therapeutic candidates: ADS032, a first-in-class dual inflammasome inhibitor small molecule targeting respiratory and dermal inflammation, and ADS024, an orally dosed single-strain live biotherapeutic product (SS-LBP) targeting neurodegenerative and neuroinflammatory diseases through G-protein coupled receptor agonism.
Differentiator
Problem solved
Functional benefit
Products and services
- ADS032
Quantifiable outcome
- ADS024 demonstrated efficacy in 12 separate animal studies across 8 distinct neurodegenerative and neuroinflammatory disease models
Companies that use Adiso Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Adiso Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Adiso Therapeutics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor.
- UMass Chan MedicalminorAcademic medical center partnership listed as an institutional partner. Specific collaboration details not provided in available sources.
- Hudson InstituteminorResearch institute partnership listed as an institutional partner. Specific collaboration details not provided in available sources.
- University of EdinburghminorAcademic institution partnership listed as an institutional partner. Specific collaboration details not provided in available sources.
- University College CorkminorAcademic institution partnership listed as an institutional partner. Specific collaboration details not provided in available sources.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Adiso Therapeutics competitors and assessment
Company assessmentDirect peers
- IFM Therapeutics: Pioneer in inflammasome (NLRP3, NLRP1, cGAS) small-molecule therapeutics, acquired by Novartis in 2019 for over $1.6B. Directly comparable to Adiso as the most prominent inflammasome-focused biotech pursuing similar NLRP targets in inflammatory disease.
- Olatec Therapeutics: Clinical-stage biotech developing dapansutrile and a pipeline of NLRP3 inflammasome inhibitors for inflammatory diseases. Directly comparable to Adiso's ADS032 program as a small-molecule inflammasome inhibitor in inflammatory indications.
- NodThera: UK-based clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors for inflammatory and neuroinflammatory diseases. Directly comparable mechanism and indication overlap to Adiso's ADS032 program.
- Inflazome: Ireland-based NLRP3 inflammasome inhibitor developer acquired by Roche in 2020 for approximately €380M. Directly comparable small-molecule inflammasome approach and was Adiso's University College Cork collaborator's regional ecosystem peer.
- Vedanta Biosciences: Clinical-stage developer of defined live biotherapeutic products for immune-mediated diseases. Directly comparable to Adiso's ADS024 as an LBP platform pursuing inflammatory indications through microbiome mechanisms.
- Seres Therapeutics: Clinical-stage microbiome therapeutics company developing live biotherapeutic products for inflammatory and infectious diseases (including approved VOWST). Directly comparable LBP modality and inflammatory-disease focus to ADS024.
- Finch Therapeutics: Developer of live biotherapeutic products for inflammatory bowel disease and other inflammatory conditions. Directly comparable LBP modality to ADS024, though Finch has significantly restructured, reflecting broader LBP industry risk.
Emerging players
- Assembly Biosciences: Biotech with a microbiome-derived therapeutics platform pursuing inflammatory and immunology indications. Comparable LBP-adjacent approach to ADS024, though focused on different mechanisms.
- Axial Therapeutics: Clinical-stage biotech developing gut-brain axis therapies for neurodevelopmental and neurodegenerative conditions. Comparable to ADS024's neurodegenerative disease focus via a microbiome mechanism.
- Amylyx Pharmaceuticals: Public biopharmaceutical company developing therapies for neurodegenerative diseases (notably ALS). Comparable indication overlap with ADS024's neurodegenerative disease programs and was a Morningside Ventures portfolio company alongside Adiso's leadership network.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Adiso Therapeutics social profiles
Digital presenceAdiso Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adiso Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
Adiso Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adiso Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adiso Therapeutics
What does Adiso Therapeutics do?
Adiso Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of multi-modal therapeutic agents with novel mechanisms of action to treat inflammatory diseases. Its core assets are ADS032, a first-in-class dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for respiratory and dermal inflammation, and ADS024, an orally dosed single-strain live biotherapeutic product (SS-LBP) that acts via selective G-protein coupled receptor agonism and has demonstrated efficacy across multiple neurodegenerative disease models.
Is Adiso Therapeutics a public or private company?
Adiso Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Adiso Therapeutics founded?
Adiso Therapeutics was founded in 2022. It employs 11 to 50 people.
Where is Adiso Therapeutics based?
Adiso Therapeutics is headquartered in Concord, United States, in the North America region.
Who are Adiso Therapeutics's main competitors?
Direct peers on record are IFM Therapeutics, Olatec Therapeutics, NodThera, Inflazome, Vedanta Biosciences, Seres Therapeutics and Finch Therapeutics. Emerging players are Assembly Biosciences, Axial Therapeutics and Amylyx Pharmaceuticals.
Does Adiso Therapeutics have an API?
No public API is recorded for Adiso Therapeutics.